Us Congress 2025-2026 Regular Session

Us Congress House Bill HB796

Introduced
1/28/25  

Caption

Second Chance for Moms Act

Impact

If enacted, the bill would require the Food and Drug Administration (FDA) to alter the labeling of mifepristone to include this warning, effectively reshaping how medical professionals and patients understand the uses and effects of this drug. By introducing a federally supported hotline for abortion pill reversal, the legislation aims to provide accessible options for women who may regret their decision to take mifepristone. However, this could lead to conflicting medical advice, as the effectiveness and safety of such reversal methods are debated within the medical community.

Summary

House Bill 796, titled the 'Second Chance for Moms Act of 2025', proposes significant amendments to existing federal regulations regarding the use of the drug mifepristone. This bill seeks to include a specific warning label on mifepristone packaging indicating that its abortifacient effects can potentially be counteracted by the use of natural progesterone. The proponents of this legislation argue that such information could increase the chances of fetal survival and enhance choices available to women during the early stages of pregnancy. Furthermore, the bill mandates the creation of a nationwide hotline that women can call to receive information about reversing the effects of mifepristone.

Contention

The bill has sparked considerable debate regarding reproductive rights and access to abortion services. Advocates for the bill in the legislative discussions highlight the importance of providing women with all potential options pertaining to their health choices. In contrast, opponents argue that the legislation might spread misinformation about the safety and efficacy of mifepristone and could lead to increased stigma surrounding abortion procedures. The potential for a hotline that directs women to providers offering 'reversal' services raises ethical concerns, particularly regarding the reliability of the treatments being offered and their implications for women's health and autonomy.

Congress_id

119-HR-796

Policy_area

Health

Introduced_date

2025-01-28

Companion Bills

No companion bills found.

Previously Filed As

US HB7823

Second Chance for Moms Act

US HB983

Second Chance at Life Act of 2023

US HB10370

To amend the Federal Food, Drug, and Cosmetic Act to establish certain labeling requirements for caffeine, and for other purposes.

US HB10526

To amend the Social Security Act to establish a Medicare for America health program to provide for comprehensive health coverage for all Americans.

US HB517

Standing with Moms Act

US HB9161

Health Equity and Accountability Act of 2024 CHANGE Act Correcting Hurtful and Alienating Names in Government Expression Act Immigrants’ Mental Health Act of 2024 Menstrual Equity For All Act of 2024 Real Education and Access for Healthy Youth Act of 2024 Data To Save Moms Act CARE for Moms Act Community Access, Resources, and Empowerment for Moms Act Senior Hunger Prevention Act of 2024 Universal School Meals Program Act of 2024

US HB3433

Give Kids a Chance Act of 2024

US HB7877

Second Chance at Public Service Loan Forgiveness Act

US HB9879

SIMSA Act of 2024 Stop the Importation and Manufacturing of Synthetic Analogues Act of 2024

US SB4296

MOMS Act More Opportunities for Moms to Succeed Act

Similar Bills

No similar bills found.